Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Neoadjuvant or adjuvant multimodality therapy in oesophageal cancer is introduced in an effort to improve prognosis. However, in a substantial fraction of patients there is no response to this non-surgical therapy. Non-invasive imaging modalities such as computed tomography (CT), endoscopic ultrasound (EUS) and 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) have been evaluated for assessing patient response to therapy, and these are described in this review. Currently, FDG-PET seems to be the best available tool for neoadjuvant therapy response assessment in oesophageal cancer.
Sloof
Gerrit W
GW
Department of Diagnostic Imaging/Nuclear Medicine, Academic Medical Centre/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. g.w.sloof@amc.uva.nl
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000628:therapy; D002986:Clinical Trials as Topic; D019160:Endosonography; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D020360:Neoadjuvant Therapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18